Limits...
Development of a Multiparametric Voxel-Based Magnetic Resonance Imaging Biomarker for Early Cancer Therapeutic Response Assessment.

Galbán CJ, Lemasson B, Hoff BA, Johnson TD, Sundgren PC, Tsien C, Chenevert TL, Ross BD - Tomography (2015)

Bottom Line: For comparison, single-biomarker PRMs were also evaluated in this study.The simultaneous analysis of ADC and rCBV by the mPRM approach was found to improve the predictive potential for patient survival over single PRM measures.With an array of quantitative imaging parameters being evaluated as biomarkers of therapeutic response, mPRM shows promise as a new methodology for consolidating physiologically distinct imaging parameters into a single interpretable and quantitative metric.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Radiology, University of Michigan, Ann Arbor, MI.

ABSTRACT

Quantitative magnetic resonance imaging (MRI)-based biomarkers, which capture physiological and functional tumor processes, were evaluated as imaging surrogates of early tumor response following chemoradiotherapy in glioma patients. A multiparametric extension of a voxel-based analysis, referred as the parametric response map (PRM), was applied to quantitative MRI maps to test the predictive potential of this metric for detecting response. Fifty-six subjects with newly diagnosed high-grade gliomas treated with radiation and concurrent temozolomide were enrolled in a single-site prospective institutional review board-approved MRI study. Apparent diffusion coefficient (ADC) and relative cerebral blood volume (rCBV) maps were acquired before therapy and 3 weeks after therapy was initiated. Multiparametric PRM (mPRM) was applied to both physiological MRI maps and evaluated as an imaging biomarker of patient survival. For comparison, single-biomarker PRMs were also evaluated in this study. The simultaneous analysis of ADC and rCBV by the mPRM approach was found to improve the predictive potential for patient survival over single PRM measures. With an array of quantitative imaging parameters being evaluated as biomarkers of therapeutic response, mPRM shows promise as a new methodology for consolidating physiologically distinct imaging parameters into a single interpretable and quantitative metric.

No MeSH data available.


Related in: MedlinePlus

Representative slices from patients identified as responders and nonresponders by mPRM. (A) Presented are T1-weighted post-Gd axial slices with a tumor contour generated from intersecting pretreatment and 3-weeks-of-treatment contours and (B) mPRM overlays with (C) a corresponding mPRM scatter plot for patients identified by mPRM as responder (top) or nonresponder (bottom). The responder was identified as having relative tumor volumes of 10% and 2% for mPRMADC+/rCBV0 and mPRMADC0/rCBV−, respectively. In contrast, the nonresponder had relative tumor volumes of 0% and 14% for mPRMADC+/rCBV0 and mPRMADC0/rCBV−, respectively. Both responders and nonresponders were diagnosed as having stable disease by the Macdonald criteria yet had overall survivals of 64 and 7.1 months, respectively. Scatter plot axes are presented as pretherapy ADC (ie, baseline) for the x-axis and 3-week follow-up ADC for the y-axis. Color coding is based on the 3-color mPRM classification model shown in Figure 2B.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4643274&req=5

Figure 3: Representative slices from patients identified as responders and nonresponders by mPRM. (A) Presented are T1-weighted post-Gd axial slices with a tumor contour generated from intersecting pretreatment and 3-weeks-of-treatment contours and (B) mPRM overlays with (C) a corresponding mPRM scatter plot for patients identified by mPRM as responder (top) or nonresponder (bottom). The responder was identified as having relative tumor volumes of 10% and 2% for mPRMADC+/rCBV0 and mPRMADC0/rCBV−, respectively. In contrast, the nonresponder had relative tumor volumes of 0% and 14% for mPRMADC+/rCBV0 and mPRMADC0/rCBV−, respectively. Both responders and nonresponders were diagnosed as having stable disease by the Macdonald criteria yet had overall survivals of 64 and 7.1 months, respectively. Scatter plot axes are presented as pretherapy ADC (ie, baseline) for the x-axis and 3-week follow-up ADC for the y-axis. Color coding is based on the 3-color mPRM classification model shown in Figure 2B.

Mentions: Figure 3 presents representative axial mPRM slices and corresponding scatter plots from 2 patients in which both indices of mPRM identified each patient as a responder or nonresponder 3 weeks into therapy. Figure 2A shows the color coding for the 3-color model. The responder was found to have an mPRMADC+/rCBV0 at 10% of the tumor volume, with 2% of the tumor classified as mPRMADC0/rCBV−. In contrast, the tumor volume from the nonresponder consisted of less than 1% of mPRMADC+/rCBV0, yet 14% consisted of mPRMADC0/rCBV−. Although both patients were diagnosed as having stable disease by the Macdonald criteria, the overall survivals were quite different, with the responder and nonresponder having survival times of 64 and 7 months, respectively.


Development of a Multiparametric Voxel-Based Magnetic Resonance Imaging Biomarker for Early Cancer Therapeutic Response Assessment.

Galbán CJ, Lemasson B, Hoff BA, Johnson TD, Sundgren PC, Tsien C, Chenevert TL, Ross BD - Tomography (2015)

Representative slices from patients identified as responders and nonresponders by mPRM. (A) Presented are T1-weighted post-Gd axial slices with a tumor contour generated from intersecting pretreatment and 3-weeks-of-treatment contours and (B) mPRM overlays with (C) a corresponding mPRM scatter plot for patients identified by mPRM as responder (top) or nonresponder (bottom). The responder was identified as having relative tumor volumes of 10% and 2% for mPRMADC+/rCBV0 and mPRMADC0/rCBV−, respectively. In contrast, the nonresponder had relative tumor volumes of 0% and 14% for mPRMADC+/rCBV0 and mPRMADC0/rCBV−, respectively. Both responders and nonresponders were diagnosed as having stable disease by the Macdonald criteria yet had overall survivals of 64 and 7.1 months, respectively. Scatter plot axes are presented as pretherapy ADC (ie, baseline) for the x-axis and 3-week follow-up ADC for the y-axis. Color coding is based on the 3-color mPRM classification model shown in Figure 2B.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4643274&req=5

Figure 3: Representative slices from patients identified as responders and nonresponders by mPRM. (A) Presented are T1-weighted post-Gd axial slices with a tumor contour generated from intersecting pretreatment and 3-weeks-of-treatment contours and (B) mPRM overlays with (C) a corresponding mPRM scatter plot for patients identified by mPRM as responder (top) or nonresponder (bottom). The responder was identified as having relative tumor volumes of 10% and 2% for mPRMADC+/rCBV0 and mPRMADC0/rCBV−, respectively. In contrast, the nonresponder had relative tumor volumes of 0% and 14% for mPRMADC+/rCBV0 and mPRMADC0/rCBV−, respectively. Both responders and nonresponders were diagnosed as having stable disease by the Macdonald criteria yet had overall survivals of 64 and 7.1 months, respectively. Scatter plot axes are presented as pretherapy ADC (ie, baseline) for the x-axis and 3-week follow-up ADC for the y-axis. Color coding is based on the 3-color mPRM classification model shown in Figure 2B.
Mentions: Figure 3 presents representative axial mPRM slices and corresponding scatter plots from 2 patients in which both indices of mPRM identified each patient as a responder or nonresponder 3 weeks into therapy. Figure 2A shows the color coding for the 3-color model. The responder was found to have an mPRMADC+/rCBV0 at 10% of the tumor volume, with 2% of the tumor classified as mPRMADC0/rCBV−. In contrast, the tumor volume from the nonresponder consisted of less than 1% of mPRMADC+/rCBV0, yet 14% consisted of mPRMADC0/rCBV−. Although both patients were diagnosed as having stable disease by the Macdonald criteria, the overall survivals were quite different, with the responder and nonresponder having survival times of 64 and 7 months, respectively.

Bottom Line: For comparison, single-biomarker PRMs were also evaluated in this study.The simultaneous analysis of ADC and rCBV by the mPRM approach was found to improve the predictive potential for patient survival over single PRM measures.With an array of quantitative imaging parameters being evaluated as biomarkers of therapeutic response, mPRM shows promise as a new methodology for consolidating physiologically distinct imaging parameters into a single interpretable and quantitative metric.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Radiology, University of Michigan, Ann Arbor, MI.

ABSTRACT

Quantitative magnetic resonance imaging (MRI)-based biomarkers, which capture physiological and functional tumor processes, were evaluated as imaging surrogates of early tumor response following chemoradiotherapy in glioma patients. A multiparametric extension of a voxel-based analysis, referred as the parametric response map (PRM), was applied to quantitative MRI maps to test the predictive potential of this metric for detecting response. Fifty-six subjects with newly diagnosed high-grade gliomas treated with radiation and concurrent temozolomide were enrolled in a single-site prospective institutional review board-approved MRI study. Apparent diffusion coefficient (ADC) and relative cerebral blood volume (rCBV) maps were acquired before therapy and 3 weeks after therapy was initiated. Multiparametric PRM (mPRM) was applied to both physiological MRI maps and evaluated as an imaging biomarker of patient survival. For comparison, single-biomarker PRMs were also evaluated in this study. The simultaneous analysis of ADC and rCBV by the mPRM approach was found to improve the predictive potential for patient survival over single PRM measures. With an array of quantitative imaging parameters being evaluated as biomarkers of therapeutic response, mPRM shows promise as a new methodology for consolidating physiologically distinct imaging parameters into a single interpretable and quantitative metric.

No MeSH data available.


Related in: MedlinePlus